{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T17:21:41Z","timestamp":1787678501588,"version":"build-2784847793"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bioorg.2026.110187","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T23:36:57Z","timestamp":1782776217000},"page":"110187","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["New indolin-2-one and isoindoline-1,3-dione derivatives as potential anti-hepatocellular carcinoma agents targeting VEGFR-2: Synthesis, in vitro, in vivo, and in silico evaluation"],"prefix":"10.1016","volume":"180","author":[{"given":"Nayera I.","family":"Mansour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam A.","family":"Ghaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia S.","family":"El-Gohary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.110187_bb0005","doi-asserted-by":"crossref","first-page":"800","DOI":"10.3390\/nu16060800","article-title":"Healthy lifestyle and cancer risk: modifiable risk factors to prevent cancer","volume":"16","author":"Marino","year":"2024","journal-title":"Nutrients"},{"key":"10.1016\/j.bioorg.2026.110187_bb0010","first-page":"1097","article-title":"Environmental risk factors for liver cancer","volume":"10","author":"McGlynn","year":"2025","journal-title":"Hepatol"},{"key":"10.1016\/j.bioorg.2026.110187_bb0015","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jhep.2024.10.031","article-title":"Liver cancer in 2021: global burden of disease study","volume":"82","author":"Tan","year":"2025","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bioorg.2026.110187_bb0020","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1038\/s41388-021-01841-2","article-title":"Receptor tyrosine kinases and cancer: oncogenic mechanisms and therapeutic approaches","volume":"40","author":"Saraon","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.bioorg.2026.110187_bb0025","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-024-01899-w","article-title":"Therapeutic advances of targeting receptor tyrosine kinases in cancer","volume":"9","author":"Tomuleasa","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bioorg.2026.110187_bb0030","first-page":"1097","article-title":"Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti-and pro-angiogenic therapies, genes","volume":"2","author":"Shibuya","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.bioorg.2026.110187_bb0035","doi-asserted-by":"crossref","first-page":"5341","DOI":"10.3390\/molecules29225341","article-title":"Targeting vascular endothelial growth factor receptor 2 (VEGFR-2): latest insights on synthetic strategies","volume":"29","author":"Marques","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2026.110187_bb0040","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.3390\/cancers13051027","article-title":"A novel bispecific antibody targeting EGFR and VEGFR2 is effective against triple negative breast cancer via multiple mechanisms of action","volume":"13","author":"Mohan","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.bioorg.2026.110187_bb0045","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.21873\/anticanres.17009","article-title":"Current roles of ramucirumab in the sequential treatment of unresectable hepatocellular carcinoma","volume":"44","author":"Koizumi","year":"2024","journal-title":"Anticancer Res."},{"key":"10.1016\/j.bioorg.2026.110187_bb0050","doi-asserted-by":"crossref","first-page":"5712","DOI":"10.1080\/07391102.2021.1872417","article-title":"Exploration of structural requirements for the inhibition of VEGFR-2 tyrosine kinase: binding site analysis of type II, \u2018DFG-out\u2019 inhibitors","volume":"40","author":"Modi","year":"2022","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.bioorg.2026.110187_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.medidd.2019.100009","article-title":"Vascular endothelial growth factor receptor (VEGFR-2)\/KDR inhibitors: medicinal chemistry perspective","volume":"2","author":"Modi","year":"2019","journal-title":"Med. Drug Discov."},{"key":"10.1016\/j.bioorg.2026.110187_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12272-025-01545-1","article-title":"Targeting vascular endothelial growth receptor-2 (VEGFR-2): structural biology, functional insights, and therapeutic resistance","volume":"48","author":"Shah","year":"2025","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.bioorg.2026.110187_bb0065","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.bbrc.2007.02.156","article-title":"Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor","volume":"356","author":"Roskoski","year":"2007","journal-title":"Biochem. Biophys. Res."},{"key":"10.1016\/j.bioorg.2026.110187_bb0070","doi-asserted-by":"crossref","first-page":"24460","DOI":"10.1038\/srep24460","article-title":"Discovery of potent VEGFR-2 inhibitors based on furopyrimidine and thienopyrimidne scaffolds as cancer targeting agents","volume":"6","author":"Aziz","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2026.110187_bb0075","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s11523-017-0484-7","article-title":"Sorafenib: a review in hepatocellular carcinoma","volume":"12","author":"Keating","year":"2017","journal-title":"Target. Oncol."},{"key":"10.1016\/j.bioorg.2026.110187_bb0080","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1080\/17568919.2025.2485863","article-title":"Design and synthesis of thiadiazoles as anticancer, apoptotic, and VEGFR-2 inhibitors","volume":"17","author":"Elgammal","year":"2025","journal-title":"Fut. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110187_bb0085","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202300269","article-title":"Design, synthesis, and evaluation of new benzimidazole thiourea derivatives as antitumor agents","volume":"356","author":"Aboutaleb","year":"2023","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.bioorg.2026.110187_bb0090","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.201900367","article-title":"Recent advances in isatin hybrids as potential anticancer agents","volume":"353","author":"Ding","year":"2020","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.bioorg.2026.110187_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.inoche.2022.109606","article-title":"Spectroscopic investigation, thermal, molecular structure, antimicrobial and anticancer activity with modelling studies of some metal complexes derived from isatin Schiff base ligand","volume":"141","author":"Mohamed","year":"2022","journal-title":"Inorg. Chem. Commun."},{"key":"10.1016\/j.bioorg.2026.110187_bb0100","doi-asserted-by":"crossref","first-page":"32188","DOI":"10.1039\/D5RA05002B","article-title":"A comprehensive review and recent advances on isatin-based compounds as a versatile framework for anticancer therapeutics (2020\u20132025)","volume":"15","author":"Alshams","year":"2025","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioorg.2026.110187_bb0105","doi-asserted-by":"crossref","first-page":"96","DOI":"10.2174\/0115680266311332240722065652","article-title":"Synthesis of isatin-derived heterocycles with promising anticancer activities","volume":"25","author":"Banerjee","year":"2025","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110187_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107644","article-title":"Novel imidazo[2,1-b]thiazoles and imidazo[1,2-a]pyridines tethered with indolinone motif as VEGFR-2 inhibitors and apoptotic inducers: design, synthesis and biological evaluations","volume":"151","author":"Elkotamy","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110187_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108231","article-title":"New indolin-2-ones, possessing sunitinib scaffold as HDAC inhibitors and anti-cancer agents with potential VEGFR inhibition activity; design, synthesis and biological evaluation","volume":"156","author":"Yousefian","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110187_bb0120","doi-asserted-by":"crossref","first-page":"18872","DOI":"10.1021\/acsomega.0c02038","article-title":"Dual targeting of VEGFR2 and C-met kinases via the design and synthesis of substituted 3-(triazolo-thiadiazin-3-yl) indolin-2-one derivatives as angiogenesis inhibitors","volume":"5","author":"Mohamady","year":"2020","journal-title":"ACS Omega"},{"key":"10.1016\/j.bioorg.2026.110187_bb0125","doi-asserted-by":"crossref","DOI":"10.3390\/molecules30051105","article-title":"Design, synthesis, and cytotoxicity evaluation of novel indolin-2-one based molecules on hepatocellular carcinoma HepG2 cells as protein kinase inhibitors","volume":"30","author":"Kandeel","year":"2025","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2026.110187_bb0130","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1080\/14756366.2022.2110869","article-title":"New quinoline and isatin derivatives as apoptotic VEGFR-2 inhibitors: design, synthesis, anti-proliferative activity, docking, ADMET, toxicity, and MD simulation studies","volume":"37","author":"Elkaeed","year":"2022","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110187_bb0135","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejmech.2015.05.040","article-title":"Indoline ureas as potential anti-hepatocellular carcinoma agents targeting VEGFR-2: synthesis, in vitro biological evaluation and molecular docking","volume":"100","author":"Eldehna","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110187_bb0140","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1080\/14756366.2021.2017911","article-title":"Synthesis, biological evaluation, and molecular docking of new series of antitumor and apoptosis inducers designed as VEGFR-2 inhibitors","volume":"37","author":"Abdallah","year":"2022","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110187_bb0145","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2147\/DDDT.S344750","article-title":"New series of VEGFR-2 inhibitors and apoptosis enhancers: design, synthesis and biological evaluation","volume":"16","author":"Abdallah","year":"2023","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.bioorg.2026.110187_bb0150","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s12253-016-0059-4","article-title":"Strong correlation between mRNA expression levels of HIF-2\u03b1, VEGFR1, VEGFR2 and MMP2 in laryngeal carcinoma","volume":"22","author":"Popov","year":"2016","journal-title":"Pathol. Oncol. Res."},{"key":"10.1016\/j.bioorg.2026.110187_bb0155","first-page":"63","article-title":"Microvascular density and immunohistochemical expression of VEGF, VEGFR-1 and VEGFR-2 in benign prostatic hyperplasia, high-grade prostate intraepithelial neoplasia and prostate cancer","volume":"69","author":"Grivas","year":"2016","journal-title":"Cent. Eur. J. Urol."},{"key":"10.1016\/j.bioorg.2026.110187_bb0160","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1007\/s10147-019-01495-x","article-title":"Serum vascular endothelial growth factor a and vascular endothelial growth factor receptor 2 as prognostic biomarkers for uterine cervical cancer","volume":"24","author":"Sawada","year":"2019","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.110187_bb0165","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1111\/liv.12778","article-title":"Expression of pERK and VEGFR-2 in advanced hepatocellular carcinoma and resistance to sorafenib treatment","volume":"35","author":"Negri","year":"2015","journal-title":"Liver Int."},{"key":"10.1016\/j.bioorg.2026.110187_bb0170","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1186\/s12885-017-3578-9","article-title":"VEGFR2 regulates endothelial differentiation of colon cancer cells","volume":"17","author":"Liu","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bioorg.2026.110187_bb0175","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.prp.2015.04.003","article-title":"Expression and prognostic significance of VEGFR-2 in breast cancer","volume":"211","author":"Yan","year":"2015","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.bioorg.2026.110187_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105966","article-title":"New phthalimide-based derivatives as EGFR-TK inhibitors: synthesis, biological evaluation, and molecular modeling study","volume":"127","author":"Mansour","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110187_bb0185","article-title":"Dual topoisomerase II\u03b1\/EGFR-TK inhibitors: synthesis, biological evaluation, and in silico studies of new thiadiazolo[3,2-a]pyrimidinone derivatives as potential anticancer agents","volume":"169","author":"Mansour","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110187_bb0190","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1081\/SCC-120015563","article-title":"A convenient synthesis of 1-alkyl-1-phenylhydrazines from N-aminophthalimide","volume":"33","author":"Nara","year":"2003","journal-title":"Synth. Commun."},{"key":"10.1016\/j.bioorg.2026.110187_bb0195","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays","volume":"65","author":"Mosmann","year":"1983","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.bioorg.2026.110187_bb0200","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0022-1759(86)90368-6","article-title":"Rapid colorimetric assay for cell growth and survival: modifications to the tetrazolium dye procedure giving improved sensitivity and reliability","volume":"89","author":"Denizot","year":"1986","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.bioorg.2026.110187_bb0205","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1093\/toxres\/tfab094","article-title":"The modulatory effect of bee honey against diethyl nitrosamine and carbon tetrachloride instigated hepatocellular carcinoma in Wistar rats","volume":"10","author":"Abouzed","year":"2021","journal-title":"Toxicol. Res."},{"key":"10.1016\/j.bioorg.2026.110187_bb0210","first-page":"167","article-title":"Biochemical roles of liver enzymes in hepatocellular injury and cholestasis","volume":"2","author":"Juraev","year":"2026","journal-title":"J. Clin. Biomed. Res."},{"key":"10.1016\/j.bioorg.2026.110187_bb0215","first-page":"247","article-title":"Flow cytometric DNA analysis of human cancer cell lines. In cancer cell culture: methods and protocols","volume":"88","author":"Mullen","year":"2004","journal-title":"Methods Mol. Med."},{"key":"10.1016\/j.bioorg.2026.110187_bb0220","first-page":"359","article-title":"Flow cytometric DNA analysis of human cancers and cell lines. In cancer cell culture: methods and protocols","volume":"731","author":"Krueger","year":"2011","journal-title":"Methods Mol. Med."},{"key":"10.1016\/j.bioorg.2026.110187_bb0225","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.ejmech.2013.04.006","article-title":"Synthesis, interaction with DNA, cytotoxicity, cell cycle arrest and apoptotic inducing properties of ruthenium(II) molecular \u201clight switch\u201d complexes","volume":"64","author":"Devi","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110187_bb0230","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/1756-9966-30-87","article-title":"Apoptosis in cancer: from pathogenesis to treatment","volume":"30","author":"Wong","year":"2011","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110187_bb0235","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.3390\/ijms23031328","article-title":"The apoptosis paradox in cancer","volume":"23","author":"Morana","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2026.110187_bb0240","doi-asserted-by":"crossref","first-page":"205","DOI":"10.15171\/apb.2019.024","article-title":"Understanding apoptosis and apoptotic pathways targeted cancer therapeutics","volume":"9","author":"Jan","year":"2019","journal-title":"Adv. Pharm. Bull."},{"key":"10.1016\/j.bioorg.2026.110187_bb0245","doi-asserted-by":"crossref","first-page":"5805","DOI":"10.1007\/s12035-023-03433-5","article-title":"A review on caspases: key regulators of biological activities and apoptosis","volume":"60","author":"Sahoo","year":"2023","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.bioorg.2026.110187_bb0250","doi-asserted-by":"crossref","first-page":"783","DOI":"10.2174\/1389203724666230227115305","article-title":"Caspase-3 activators as anticancer agents","volume":"24","author":"Srivastava","year":"2023","journal-title":"Curr. Protein Pept. Sci."},{"key":"10.1016\/j.bioorg.2026.110187_bb0255","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00204-014-1448-7","article-title":"The mystery of BCL2 family: BCL-2 proteins and apoptosis: an update","volume":"89","author":"Siddiqui","year":"2015","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.bioorg.2026.110187_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114184","article-title":"Trends in targeting Bcl-2 anti-apoptotic proteins for cancer treatment","volume":"232","author":"Zhang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110187_bb0265","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1517\/17460441.3.6.607","article-title":"The challenge of selecting protein kinase assays for lead discovery optimization","volume":"3","author":"Ma","year":"2008","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.bioorg.2026.110187_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2024.129971","article-title":"Discovery of novel, orally bioavailable phenylacetamide derivatives as multikinase inhibitors and in vivo efficacy study in hepatocellular carcinoma animal models","volume":"113","author":"Das","year":"2024","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110187_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.106310","article-title":"Design, synthesis and molecular modeling study of certain EGFR inhibitors with a quinazolinone scaffold as anti-hepatocellular carcinoma and radio-sensitizers","volume":"131","author":"Ghorab","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110187_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2022.115825","article-title":"Biejiajian pill inhibits progression of hepatocellular carcinoma by downregulating PDGFR\u03b2 signaling in cancer-associated fibroblasts","volume":"301","author":"Chen","year":"2023","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.bioorg.2026.110187_bb0285","doi-asserted-by":"crossref","first-page":"12314","DOI":"10.1021\/acs.jmedchem.4c01004","article-title":"Discovery of potent and selective c-met degraders for hepatocellular carcinoma treatment","volume":"67","author":"Min","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110187_bb0290","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1021\/ml500394m","article-title":"Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization","volume":"6","author":"Okamoto","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110187_bb0295","unstructured":"MOE 2024.06 Of Chemical Computing Group. Inc. https:\/\/www.chemcomp.com\/."},{"key":"10.1016\/j.bioorg.2026.110187_bb0300","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.neuron.2018.08.011","article-title":"Molecular dynamics simulation for all","volume":"99","author":"Hollingsworth","year":"2018","journal-title":"Neuron"},{"key":"10.1016\/j.bioorg.2026.110187_bb0305","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","article-title":"GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers","volume":"1","author":"Abraham","year":"2015","journal-title":"SoftwareX"},{"key":"10.1016\/j.bioorg.2026.110187_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2021.104851","article-title":"In silico methods and tools for drug discovery","volume":"137","author":"Shaker","year":"2021","journal-title":"Comput. Biol. Med."},{"key":"10.1016\/j.bioorg.2026.110187_bb0315","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ddtec.2004.11.007","article-title":"Lead- and drug-like compounds: the rule-of-five revolution","volume":"1","author":"Lipinski","year":"2004","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.bioorg.2026.110187_bb0320","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/jm020017n","article-title":"Molecular properties that influence the oral bioavailability of drug candidates","volume":"45","author":"Veber","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110187_bb0340","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1021\/jm301297f","article-title":"Demystifying brain penetration in central nervous system drug discovery: miniperspective","volume":"56","author":"Di","year":"2013","journal-title":"J. Med. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826007236?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826007236?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T16:46:41Z","timestamp":1787676401000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826007236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":65,"alternative-id":["S0045206826007236"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110187","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New indolin-2-one and isoindoline-1,3-dione derivatives as potential anti-hepatocellular carcinoma agents targeting VEGFR-2: Synthesis, in vitro, in vivo, and in silico evaluation","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110187","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110187"}}